D. E. Shaw & Co. Inc. Raises Stock Position in Cryoport, Inc. (NASDAQ:CYRX)

D. E. Shaw & Co. Inc. raised its position in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 20.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 408,385 shares of the company's stock after purchasing an additional 68,474 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.83% of Cryoport worth $3,177,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Cadian Capital Management LP lifted its holdings in Cryoport by 14.1% during the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company's stock valued at $38,332,000 after purchasing an additional 609,021 shares in the last quarter. Deutsche Bank AG lifted its holdings in Cryoport by 0.9% during the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company's stock valued at $10,870,000 after purchasing an additional 12,864 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Cryoport by 8.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 850,216 shares of the company's stock valued at $6,615,000 after buying an additional 63,301 shares during the last quarter. LPL Financial LLC raised its position in shares of Cryoport by 1,366.1% during the fourth quarter. LPL Financial LLC now owns 436,766 shares of the company's stock valued at $3,398,000 after buying an additional 406,976 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Cryoport by 0.4% during the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock valued at $3,012,000 after buying an additional 1,512 shares during the last quarter. Hedge funds and other institutional investors own 92.90% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CYRX shares. Morgan Stanley reduced their target price on Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a report on Monday, May 5th. UBS Group boosted their price target on shares of Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Roth Mkm restated a "buy" rating and issued a $15.00 price target on shares of Cryoport in a research report on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and issued a $11.00 price target on shares of Cryoport in a research report on Thursday, May 8th. Finally, Guggenheim restated a "buy" rating and issued a $10.00 price target on shares of Cryoport in a research report on Wednesday, April 16th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $11.00.

Cryoport Stock Performance

Shares of NASDAQ CYRX traded down $0.22 during mid-day trading on Friday, hitting $6.00. The stock had a trading volume of 120,607 shares, compared to its average volume of 542,761. Cryoport, Inc. has a twelve month low of $4.58 and a twelve month high of $11.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The firm has a market cap of $300.82 million, a PE ratio of -1.78 and a beta of 1.92. The company has a 50 day moving average of $5.94 and a two-hundred day moving average of $6.84.

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The firm had revenue of $41.04 million for the quarter, compared to analysts' expectations of $56.19 million. Research analysts predict that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jerrell Shelton sold 4,620 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now owns 765,399 shares of the company's stock, valued at approximately $4,814,359.71. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders sold 19,830 shares of company stock valued at $118,353. 10.00% of the stock is owned by corporate insiders.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.